Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Hurricane Maria Continues to Wreak Havoc on the Medical Industry

Though it has been nearly four months since Hurricane Maria made landfall in Puerto Rico, the effects continue to devastate the medical industry both on the island and the mainland. The power grid on the island remains mostly inoperable, leaving Puerto Rico’s many medical equipment manufacturing plants unable to operate. The United States Food and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Though it has been nearly four months since Hurricane Maria made landfall in Puerto Rico, the effects continue to devastate the medical industry both on the island and the mainland. The power grid on the island remains mostly inoperable, leaving Puerto Rico’s many medical equipment manufacturing plants unable to operate.

The United States Food and Drug Administration (FDA) has confirmed that the U.S. territory of Puerto Rico typically produces about $40 billion worth of pharmaceuticals each year. This amounts to more pharmaceutical production than any one of the 50 states, any other U.S. territory, or any single foreign country. Unfortunately, these productive manufacturing facilities have mostly shut down since Hurricane Maria hit land nearly four months ago, and the plants that are in operation continue to rely on generators.

Three of the affected manufacturing plants are home to Baxter, one of the most significant suppliers of IV bags. All three of Baxter’s plants on the island were forced to stall manufacturing. While two stations are now up and running on generators, the other remains closed.

According to the New York Times, about 10% of the drugs that Americans consume every day are made in Puerto Rico. While the island continues to recover from the devastating hurricane, medical professionals on the mainland should expect low supply, back orders, and price increases.

Unfortunately, these drug shortages could affect Accutome by Keeler and its customers. Ophthalmology offices should be aware of this backup and prepare accordingly. These professionals should expect Accutome and other providers to be out of certain products like morphine, IV solutions, mesh, surgical scalpels, and more. While the provider works hard to secure these products for customers.

The FDA is working with the manufacturers in Puerto Rico to get production back on track. The agency is currently monitoring a total of 90 products in hopes of stopping shortages before they become critical. The administration is also working with Puerto Rico to get manufacturing back on track.

“We continue to work closely with federal and Puerto Rican authorities to address the needs of manufacturers on the island for power and other resources. … Mitigating medical product shortages will require a sustained effort by the industry, the agency, and other partners as we work with manufacturers to return to production levels that adequately meet the needs of patients,” FDA Commissioner Scott Gottlieb, MD, said in a statement.

Thanks to generous tax incentives, Puerto Rico is home to many big-name manufacturers such as Johnson & Johnson, Pfizer, and Abbott Medical Optics. However, because only about half of these manufacturers are producing right now, medical professionals across the United States are destined to feel the shortage.

Since 2014, the FDA has been monitoring Puerto Rico for potential drug shortages. But Hurricane Maria turned a potential problem into a significant and immediate emergency. This shortage has made it difficult for cancer patients to receive proper care because Baxter makes the saline bags used for treatments. Furthermore, care of premature babies has been placed in jeopardy due to the shortage.

Accutome by Keeler is in its fourth decade of operation and will not allow this hurricane to end its reputation as a leader in the ophthalmic industry. With superior customer service, quality, and innovation, the company will continue to serve its customers through this crisis. Customers should feel free to contact their representatives with any questions they may have.

Accutome by Keeler stands with the people of Puerto Rico, its customers, and its commitment to service. While Hurricane Maria may have disrupted supplies, customers will not see a disruption in the service they have come to expect.

Read more at accutome.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The healthcare industry faces significant consequences when delayed decision-making occurs. Prompt and efficient action is crucial to prevent adverse impacts on patient care and operational efficiency. Addressing this issue requires a commitment to more agile and informed decision processes.

  • 01Delayed decision-making in healthcare can lead to negative impacts on patient care and operational efficiency.
  • 02Healthcare organizations are encouraged to adopt agile decision-making processes to improve effectiveness.
  • 03Implementing informed and prompt decision-making strategies can mitigate the risks of inefficiencies and poor patient outcomes.

Aug 17, 2026

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

The Centers for Medicare & Medicaid Services (CMS) launched its tech-enabled chronic care pilot program, known as the ACCESS pilot. Despite its initiation, a significant issue persists as patients struggle to find which healthcare providers are participating in the program. Meanwhile, the FDA has authorized 115 AI-based medical devices in 2021.

  • 01CMS has initiated the ACCESS pilot program to enhance chronic care management using technology.
  • 02Patients are facing challenges in identifying healthcare providers involved in the ACCESS pilot.
  • 03In 2021, the FDA authorized 115 AI-based medical devices.

Aug 17, 2026

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

BioNTech has appointed Guido Oelkers, the current CEO of Sobi, as its next chief executive. Oelkers is tasked with advancing BioNTech's oncology pipeline to achieve multiple approved products by 2030.

  • 01BioNTech has selected Guido Oelkers as its new CEO, effective soon.
  • 02Guido Oelkers aims to turn BioNTech's deep oncology pipeline into several approved products by 2030.

Aug 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512